These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37747471)

  • 21. Time kill-assays of antibiotic combinations for multidrug resistant clinical isolates of OXA-48 carbapenemase producing Klebsiella pneumoniae.
    Erdem F; Díez-Aguilar M; Oksuz L; Kayacan C; Abulaila A; Oncul O; Morosini MI; Cantón R; Aktas Z
    Acta Microbiol Immunol Hung; 2022 Sep; 69(3):215-219. PubMed ID: 35895557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment strategies for OXA-48-like and NDM producing
    Isler B; Aslan AT; Akova M; Harris P; Paterson DL
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1389-1400. PubMed ID: 36150216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic and clinical characterisation of multidrug-resistant carbapenemase-producing ST231 and ST16 Klebsiella pneumoniae isolates colonising patients at Siriraj hospital, Bangkok, Thailand from 2015 to 2017.
    Boonyasiri A; Jauneikaite E; Brinkac LM; Greco C; Lerdlamyong K; Tangkoskul T; Nguyen K; Thamlikitkul V; Fouts DE
    BMC Infect Dis; 2021 Feb; 21(1):142. PubMed ID: 33541274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical carbapenem-resistant
    Shahid M; Ahmad N; Saeed NK; Shadab M; Joji RM; Al-Mahmeed A; Bindayna KM; Tabbara KS; Dar FK
    Front Cell Infect Microbiol; 2022; 12():1033305. PubMed ID: 36304935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of NDM-1 and OXA-48 carbapenemase genes among Klebsiella pneumoniae isolates in central Iran.
    Abbasi E; Ghaznavi-Rad E
    BMC Microbiol; 2023 Apr; 23(1):98. PubMed ID: 37038144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey.
    Süzük Yıldız S; Kaşkatepe B; Şimşek H; Sarıgüzel FM
    Acta Microbiol Immunol Hung; 2019 Mar; 66(1):103-112. PubMed ID: 30403361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E.coli and Klebsiella pneumoniae by checkerboard method.
    Dhandapani S; Sistla S; Gunalan A; Manoharan M; Sugumar M; Sastry AS
    Indian J Med Microbiol; 2021 Jan; 39(1):6-10. PubMed ID: 33516606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant
    Liu E; Jia P; Li X; Zhou M; Kudinha T; Wu C; Xu Y; Yang Q
    Infect Drug Resist; 2021; 14():917-928. PubMed ID: 33707959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of
    Suich J; Mawer D; van der Woude M; Wearmouth D; Burns P; Smeets T; Barlow G
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35476672
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates.
    Papoutsaki V; Galani I; Papadimitriou E; Karantani I; Karaiskos I; Giamarellou H
    J Glob Antimicrob Resist; 2020 Mar; 20():98-104. PubMed ID: 31398495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.
    Souli M; Galani I; Boukovalas S; Gourgoulis MG; Chryssouli Z; Kanellakopoulou K; Panagea T; Giamarellou H
    Antimicrob Agents Chemother; 2011 May; 55(5):2395-7. PubMed ID: 21321144
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Zhou C; Wang Q; Jin L; Wang R; Yin Y; Sun S; Zhang J; Wang H
    Front Microbiol; 2020; 11():533209. PubMed ID: 33193122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistotyping, phenotyping and genotyping of New Delhi metallo-β-lactamase (NDM) among Gram-negative bacilli from Iranian patients.
    Shokri D; Rabbani Khorasgani M; Fatemi SM; Soleimani-Delfan A
    J Med Microbiol; 2017 Apr; 66(4):402-411. PubMed ID: 28150578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
    Laishram S; Anandan S; Devi BY; Elakkiya M; Priyanka B; Bhuvaneshwari T; Peter JV; Subramani K; Balaji V
    J Chemother; 2016 Aug; 28(4):297-303. PubMed ID: 27461479
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Goel A; Gupta V; Singhal L; Palta S; Chander J
    Indian J Med Res; 2021 Mar; 154(3):520-526. PubMed ID: 35345078
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Cebrero-Cangueiro T; Álvarez-Marín R; Labrador-Herrera G; Smani Y; Cordero-Matía E; Pachón J; Pachón-Ibáñez ME
    Front Cell Infect Microbiol; 2018; 8():363. PubMed ID: 30406040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.